Oblato gains rights to glioblastoma compound OKN-007

Oblato Inc. exercised its 2016 option to receive all rights to glioblastoma compound OKN-007 from Oklahoma Medical Research Foundation (Oklahoma City, Okla.). Oblato is a subsidiary of GtreeBNT Co. Ltd. (Seongnam, South Korea).

The foundation said OKN-007 acts on targets associated with the extracellular matrix in the transforming growth factor β 1 (TGFβ1) pathway. An IV formulation of compound is in multiple Phase I trials at the foundation; Oblato said it also intends to develop an oral formulation with clinical trials starting in April 2019...